If Sarah had the option to receive earlier intervention in the ambulance following a 911 call, or in the ER, there could be an opportunity to reduce the risks to her clinical prognosis. That is why IMMEDIATE is developing IMT-358. FDA has designated IMT-358 as a Breakthrough Therapy for the treatment of acute coronary syndrome to reduce the risk of mortality, hospitalization for heart failure, and cardiac arrest.
patients present with chest pain symptomatic of a possible heart attack (acute coronary syndrome) in the US each year.1 That’s one new patient every 4 seconds.
of all deaths worldwide are due to ACS. That makes it the No. 1 cause of mortality.2
was the aggregate cost of treating ACS in 2008. By 2035 that cost is expected to double.3
IMT-358: An investigational drug under development by IMMEDIATE Therapeutics to be administered the first hours of a developing heart attack (i.e., ACS) to provide metabolic protection to the heart muscle, potentially minimizing cardiac damage and reducing cardiac instability that can lead to cardiac arrest. The efficacy of IMT-358 is under confirmation in a planned pivotal phase 3 trial.